Protocol The attached Protocol shall be an integral part of this Agreement.
Review Protocol A narrative description of how the Claims Review was conducted and what was evaluated.
Signaling protocol The Parties will interconnect their networks using SS7 signaling where Technically Feasible and available as defined in GR 905 Telcordia Standards including ISDN User Part (ISUP) for trunk signaling and TCAP for CCS-based features in the Interconnection of their networks. All Network Operations Forum (NOF) adopted standards shall be adhered to. Where available, CenturyLink signaling services to link its Signaling Transfer Points (STPs) for CLEC switches which connect to CenturyLink’s STPs via “A” links or for CLEC’s STPs to connect to CenturyLink’s STPs via “D” links which are dedicated to the transport of signaling for local Interconnection, may be ordered from the CenturyLink Tariff.
Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.
Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.
Development Schedule The Project shall substantially comply with the specific timetables and triggers for action set forth in Article 5 of this Agreement. The parties acknowledge that, as provided in G.S. 160A-400.25(b), the failure to meet a commencement or completion date shall not, in and of itself, constitute a material breach of this Agreement pursuant to G.S. 160A-400.27 but must be judged based upon the totality of the circumstances.
Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.
Contract Database Metadata Elements Title: Great Neck Union Free School District and Great Neck Paraprofessionals Association (2011) Employer Name: Great Neck Union Free School District Union: Great Neck Paraprofessionals Association Local: Effective Date: 07/01/2011 Expiration Date: 06/30/2015 PERB ID Number: 5132 Unit Size: Number of Pages: 28 For additional research information and assistance, please visit the Research page of the Catherwood website - xxxx://xxx.xxx.xxxxxxx.xxx/library/research/ For additional information on the ILR School - xxxx://xxx.xxx.xxxxxxx.xxx/ ARTICLE# TITLE PAGE# Preamble 2 Article 1 Association Rights 2 Article 2 Board-Administration-Association Relationship and Procedures 4 Article 3 Exchange of Proposals 6 Article 4 Professionals Duties and Responsibilities of Paraprofessionals 7 Article 5 Work Assignments 8 Article 6 Annual Appointment 10 Article 7 Selection and Promotion 10 Article 8 Evaluations and Standards 11 Article 9 Procedures for Termination of Employment 11 Article 10 Conferences 12 Article 11 Human Resource File 12 Article 12 Professional Growth 13 Article 13 Sick Leave 14 Article 14 Personal Leave 16 Article 15 Other Leaves 17 Article 16 Grievance Procedures 18 Article 17 Legal Assistance 19 Article 18 Conformity to Law 19 Article 19 Health Insurance 20 Article 20 Retirement Plan 20 Article 21 Salary Schedule 21 Article 22 Seniority Policy 23 Article 23 Compensation for Financial Loss 24 Article 24 Duration of Agreement 25 Appendix A Determination of Negotiating Unit 25 Appendix B Payroll Deduction Authorization 26 Appendix C Bus Aides 26 Appendix D Salary Schedules 27
Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.
MSAA Indicator Technical Specification Document This Agreement shall be interpreted with reference to the MSAA Indicator Technical Specifications document.
